Argent Capital Management LLC Has $14.71 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Argent Capital Management LLC increased its holdings in Thermo Fisher Scientific Inc. by 2.7% in Q2, now owning 36,284 shares valued at $14.71 million.
• Analyst Ratings for Thermo Fisher have varied, with some raising the price target to $590 while others have downgraded recommendations, reflecting mixed market sentiment.
• The company declared a quarterly dividend of $0.43 per share, culminating in an annual yield of 0.4% with an ex-dividend date of September 15th.

Argent Capital Management LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 36,284 shares of the medical research company's stock after purchasing an additional 958 shares during the period. Argent Capital Management LLC's holdings in Thermo Fisher Scientific were worth $14,712,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Hoey Investments Inc. grew its position in Thermo Fisher Scientific by 11.3% in the 2nd quarter. Hoey Investments Inc. now owns 1,021 shares of the medical research company's stock worth $414,000 after purchasing an additional 104 shares in the last quarter. CHICAGO TRUST Co NA grew its position in Thermo Fisher Scientific by 51.9% in the 2nd quarter. CHICAGO TRUST Co NA now owns 1,916 shares of the medical research company's stock worth $777,000 after purchasing an additional 655 shares in the last quarter. Gries Financial LLC grew its position in Thermo Fisher Scientific by 8.7% in the 2nd quarter. Gries Financial LLC now owns 1,537 shares of the medical research company's stock worth $623,000 after purchasing an additional 123 shares in the last quarter. Golden State Equity Partners grew its position in Thermo Fisher Scientific by 210.8% in the 2nd quarter. Golden State Equity Partners now owns 3,018 shares of the medical research company's stock worth $1,224,000 after purchasing an additional 2,047 shares in the last quarter. Finally, Founders Capital Management LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $510,000. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

TMO has been the subject of a number of recent analyst reports. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Raymond James Financial reissued an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, William Blair assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Sixteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last quarter. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $474.54 on Tuesday. The firm's fifty day moving average price is $472.99 and its 200-day moving average price is $448.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market cap of $179.19 billion, a P/E ratio of 27.45, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the firm earned $5.37 EPS. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.